Avalyn Pharma Inc.

Address: 245 1st Street

Sponsor Overview

assignment

Specializations

Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases

Avalyn Pharma Inc. focuses on inhaled and nebulized therapies for idiopathic pulmonary fibrosis and broader interstitial lung diseases, with attention to progressive forms of fibrosing lung disease.

Idiopathic pulmonary fibrosis (IPF)
Interstitial lung disease (ILD)
Progressive fibrosing lung disease
Progressive pulmonary fibrosis (PPF)

The sponsor’s clinical work centers on lung scarring disorders where preserving respiratory function is a major therapeutic goal.

Antifibrotic Therapy

The company’s research portfolio includes antifibrotic medicines delivered by inhalation, with studies examining their role in managing chronic fibrotic lung conditions.

Pirfenidone solution for inhalation
Nintedanib solution
Inhaled antifibrotic treatment
Long-term tolerability

These programs reflect a therapeutic interest in treatments designed for direct pulmonary delivery in fibrosing airway and parenchymal disease.

Pulmonary Function and Disease Progression

Avalyn Pharma’s studies examine outcomes tied to lung function and progression of fibrotic disease, particularly in patients with worsening respiratory impairment.

Respiratory function preservation
Disease progression in PPF
Functional outcomes in IPF
Chronic fibrosing lung disorders

The trial portfolio is directed toward conditions where slowing decline in pulmonary capacity is clinically important.

Regulatory Access and Ongoing Treatment Continuation

The sponsor also supports studies that maintain patient access to investigational inhaled therapies for ILD and IPF during periods of continued clinical need.

Open-label extension
Continued treatment access
Safety monitoring
Therapy tolerability

Its research activity is concentrated in respiratory medicine, with a strong emphasis on fibrotic lung disease management.

Trial Name	Country	Status
A study to evaluate the safety and effectiveness of inhaled nintedanib in patients with idiopathic pulmonary fibrosis	Germany Italy Spain	Recruiting
Evaluation of Inhaled Pirfenidone (AP01) Efficacy and Safety in Progressive Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial	Belgium France Germany Italy Poland Spain The Netherlands	Not Recruiting
Evaluation of Pirfenidone Inhalation Solution (AP01) for Progressive Fibrosing Interstitial Lung Diseases, Including Idiopathic Pulmonary Fibrosis	Czechia Poland The Netherlands	Not Recruiting
Long-Term Safety and Tolerability of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis: An Open-Label Extension Study	Czechia France Germany Italy Poland Spain The Netherlands	Recruiting